趋化因子CCL20及其受体CCR6在乳腺癌患者外周血中的表达及意义

目的研究乳腺癌患者外周血中趋化因子CCL20及其受体CCR6的表达变化在乳腺癌发病机制中的作用。方法把乳腺癌患者分为2组,癌组织上有CCR6表达的为CCR6＋组,癌组织上未见有CCR6表达的为CCR6-组。采用酶联免疫吸咐试验（ELISA）检测乳腺癌患者及正常人血清中CCL20水平,同时用流式细胞仪分析外周血CD3＋T淋巴细胞表面CCR6的表达。结果 CCR6＋组患者血清CCL20水平明显高于正常对照组和CCR6-组（P均〈0.01）,各组外周血CD3＋T淋巴细胞表面CCR6的表达差异无统计学意义。结论 CCR6＋组患者血清CCL20水平升高可能在部分乳腺癌的发病过程中发挥作用。

Expression of chemokine CCL20 and its receptor CCR6 in peripheral blood from patients with breast cancer and its significance

Objective To study the role of peripheral blood chemokine CCL20 and its receptor CCR6 in the pathogenesis of breast cancer.Methods The patients with breast cancer were classified into 2 groups,according to the expression of CCR6 in breast cancer tissue.One was with positive CCR6 expression（CCR6＋ patients）,and another was without CCR6 expression（CCR6-patients）.The serum levels of CCL20 were determined by enzyme-linked immunosorbent assay（ELISA） in patients with breast cancer and healthy controls.Meanwhile,the chemokine receptor CCR6 expression on peripheral blood CD3＋ T-lymphocytes from patients and controls was analyzed by flow cytometry.Results The serum levels of CCL20 in CCR6＋ patients were significantly higher than those in CCR6-patients and controls（P〈0.01）.There was no statistical difference in the expression of CCR6 on peripheral blood CD3＋ T-lymphocytes among the 3 groups. Conclusions The increase of CCL20 in CCR6＋ patients may play a role in pathogenesis of partial breast cancer.